Cladribine: From the bench to the bedside - Focus on hairy cell leukemia

Expert Review of Anticancer Therapy

Volumn 4, Issue 5, 2004, Pages 745-757

  Greyz, Natalya ^a   Saven, Alan ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Chronic lymphocytic leukemia; Cladribine; Cutaneous T cell lymphoma; Hairy cell leukemia; Langerhans cell histiocytosis; Low grade non Hodgkin's lymphoma; Purine analogs

Indexed keywords

ALPHA INTERFERON; BL 22; CD103 ANTIGEN; CD11 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INTERLEUKIN 2 RECEPTOR; PENTOSTATIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ANEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; FEBRILE NEUTROPENIA; HAIRY CELL LEUKEMIA; HERPES SIMPLEX; HISTIOCYTOSIS X; HUMAN; LYMPHOCYTE COUNT; MONONUCLEAR CELL; MYELOID LEUKEMIA; REVIEW; SOLID TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 5444258023     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.5.745     Document Type: Review

References (90)

1. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067-1069 (1972).
2. Carson DA, Wasson DB, Kaye J et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl Acad. Sci. USA 77, 6865-6869 (1980).
3. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62(4), 737-743 (1983).
4. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 340, 952-956(1992).
5. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 75(2), 377-383 (1985).
6. Thornberry NA, Lazebnik Y, Caspases: enemies within. Science 281, 1312-1316 (1998).
7. Leoni LM, Chao Q, Cottam HB et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′ -deoxyadenosine 5′-triphosphate and cytochrome c. Proc. Natl Acad. Sci. USA 95(16), 9567-9571 (1998).
8. Ceruti S, Beltrami E, Matarrese P et al. A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2′-deoxyadenosine (Cladribine) and 2-chloroadenosine in human astrocytoma cells. Mol. Pharmacol. 63, 1437-1447 (2003).
9. Genini D, Adachi S, Chao Q et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96(10), 3537-3543 (2000).
10. Hartman WR, Hentosh R The antileukemia drug 2-chloro-2′-deoxyadenosine: an intrinsic transcriptional antagonist. Mol. Pharmacol. 65, 227-234 (2004).
11. Carrera CJ, Yamanaka H, Piro LD, Lotz M, Carson DA. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. Adv. Exp. Med. Biol. 253B, 219-225 (1989).
12. Petzer AL, Bilgeri R, Zilian U et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 78(10), 2583-2587 (1991).
13. Gorski A, Grieb P, Korczak-Kowalska G, Wierzbicki P, Stepien-Sopniewska B, Mrowiec T. Cladribine: an inhibitor of human B- and T-cell activation in vitro. Immunopharmacology 26(3), 197-202 (1993).
14. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res. 51(20), 5570-5572 (1991).
15. Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl Acad. Sci. USA 81, 2232-2236 (1984).
16. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′ -deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 10, 1514-1518 (1992).
17. Albertioni F, Juliusson G, Liliemark J. On the bioavalability of 2-chloro-2′-deoxyadenosine. The influence of food and omeprazole. Eur. J. Clin. Pharmacol. 44(6), 579-582 (1993).
18. Saven A, Cheung WK, Smith I et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J. Clin. Oncol. 14(3), 978-983 (1996).
19. Shrek R. Donnelly J. Hairy cells in blood lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. Blood 27, 199 (1966).
20. Ewald O. Die leukämische reticuloendotheliose. Deutsches Arch. Klin. Med. 142, 222-228 (1923).
21. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1, 609-630 (1958).
22. Goodman RG, Bethel JK, Saven A. Hairy cell leukemia: an update. Curr. Opin. Hematol. 10, 258-266 (2003).
23. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review of 71 cases. Ann. Intern. Med. 89, 677 (1978).
24. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract. Res. Clin. Haematol. 16(1), 41-56 (2003).
25. Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk. Lymphoma 35, 347-354 (1999).
26. Piro LD, Miller WE, Carrera CJ, Carson DA, Beutler E. Hairy cell leukemia. N. Engl. J. Med. 317, 901 (1987).
27. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 322, 1117-1121 (1990).
28. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92(6), 1918-1926 (1998).
29. Goodman GR, Burian C, Koziol JA. Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol. 21(5), 891-896 (2003).
30. Tallman MS, Hakimian D, Rademaker AW et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88(6), 1954-1959 (1996).
31. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J. Clin. Oncol. 15, 1138-1142 (1997).
32. Cheson BD, Sorensen JM, Vena DA et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C Protocol Mechanism of the National Cancer Institute: a report of 979 patients. J. Clin. Oncol. 16(9), 3007-3015 (1998).
33. Estey EH, Kurzrock R, Kantarjian HM et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79(4), 882-887 (1992).
34. Dearden CE, Matutes E, Hilditch BL et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br. J. Haematol. 106, 515-519 (1999).
35. Jehn U, Bartl R, Dietzfelbinger H et al. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Ann. Hematol. 78(3), 139-144 (1999).
36. Zinzani PL, Magagnoli M, Bendandi M et al. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica 85(9), 922-925 (2000).
37. Robak T, Blasinska-Morawiec M, Blonski J et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur. J. Haematol. 62, 49-56 (1999).
38. Van Rohr A, Schmitz SF, Tichelli A et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a Phase II study. Ann. Oncol. 13(10 , 1641-1649 (2002).
39. Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 93(8), 2471-2477 (1999).
40. + lymphocyte count in patients with hairy cell leukemia. Blood 83(10), 2906-2911 (1994).
41. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 79(4), 888-894 (1992).
42. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 83(12), 3672-3681 (1994).
43. Kurzrock R, Strom SS, Estey E et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J. Clin. Oncol. 15 (5), 1803-1810 (1997).
44. Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 92(4), 1160-1164 (1998).
45. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J. Clin. Oncol. 17(8), 2454-2460 (1999).
46. Ries LA, Miller BA, Hankey BF et al. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. National Cancer Institute, MD, USA, National Institute of Health Publication No. 94-2789 (1994).
47. Bernstein L, Newton P, Ross RK Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 50, 3605-3609(1990).
48. Federico M, Zinzani PL, Frassoldati A et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J. Clin. Oncol. 20(3), 638-646 (2002).
49. Kluin-Nelemans JC, Kester MG, Melenhorst JJ et al. Persistent clonal excess and skewed T-cell repertoire in T-cells from patients with hairy call leukemia. Blood 87, 3795-3802 (1996).
50. Van de Corput L, Falkenburg JH, Kluin-Nelemans JC. T-cell dysfunction in hairy cell leukemia: an updated review. Leuk. Lymphoma 30, 31-39 (1998).
51. Filleul B, Delannoy A, Ferrant A et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8(7), 1153-1156 (1994).
52. Ellison DJ, Sharpe RW, Robbins BA et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 84(12), 4310-4315 (1994).
53. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 87(4), 1556-1560 (1996).
54. Spiers AS, Moore D, Cassileth PA. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N. Engl. J. Med. 316, 825-830 (1987).
55. Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann. Intern. Med. 119(4), 278-283 (1993).
56. Flinn IW, Kopecky KJ, Foucar MK et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96(9 , 2981-2986 (2000).
57. Cassileth PA, Cheuvart B, Spiers AS et al. Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 9, 243-246 (1991).
58. Nieva J, Bethel K, Saven A. Phase II study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102(3), 810-813 (2003).
59. Thomas DA, O'Brien S, Bueso-Ramos C et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 102(12), 3906-3911 (2003).
60. Kreitman RJ, Wilson WH, Robbins D et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94(10), 3340-3348 (1999).
61. Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the antiCD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345 (4), 241-247 (2001).
62. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72(3), 1069-1073 (1988).
63. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma 5(Suppl.), 133-138 (1991).
64. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81(3), 597-601 (1993).
65. Juliusson G, Elmhorn-Rosenborg A. Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 327, 1056-1061 (1992).
66. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 11(4), 679-689 (1993).
67. Saven A, Lemon RH, Piro LD. 2-chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 328, 812-813 (1993).
68. O'Brien S, Kantarjian H, Estey E et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N. Engl. J. Med. 330, 319-322 (1994).
69. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol. 13(3), 570-574 (1995).
70. Robak T, Blonski JZ, Kasznicki M. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96(8), 2723-2729 (2000).
71. Kay AC, Saven A, Carrera CJ et al. 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 10(3), 371-377 (1992).
72. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 86(5), 1710-1716 (1995).
73. Jäger G, Neumeister P, Brezinschek R et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a Phase II study. J. Clin. Oncol. 20(18), 3872-3877 (2002).
74. Armitage JO, Tobinai K, Hoelzer D, Rummel MJ. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int. J. Hematol. 79(4), 311-321 (2004).
75. Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogs and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk. Res. 28(5), 429-442 (2004).
76. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80(3), 587-592 (1992).
77. O'Brien S, Kurzrock R, Duvic M et al. 2-chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84(3), 733-738 (1994).
78. Kuzel TM, Hurria A, Samuelson E et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87(3), 906-911 (1996).
79. Tobinai K, Uike N, Saburi Y et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int. J. Haematol. 77(5), 512-517 (2003).
80. Dimopoulos MA, Kantarjian H, Estey E et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Intern. Med. 118(3), 195-198 (1993).
81. Hampshire A, Saven A. Update of bolus administration of cladribine in the treatment of Waldenstrom's macroglobulinemia. Blood 102(11), 402a (2003).
82. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin. Oncol. 30(2), 243-247 (2003).
83. Saven A, Piro LD, Lemon RH et al. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 73(12), 2953-2963 (1994).
84. Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL. 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin. Oncol. 10(3), 364-370 (1992).
85. Krance RA, Hurwitz CA, Head DR et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J. Clin. Oncol. 19(11), 2804-2811 (2001).
86. Holowiecki J, Grosicki S, Robak T et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, Phase III study. Leukemia 18, 989-997 (2004).
87. Saven A. Kawasaki H, Carrera CJ et al. 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J. Clin. Oncol. 11(4), 671-678 (1993).
88. Hampshire AP, Saven A. Update of cladribine in the treatment of adults with Langerhans-cell histiocytosis (LCH). Proc. Am. Soc. Clin. Oncol. 23, 581 (2004).
89. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E. Differential in situ cytokine profiles of Langerhans-like cells and T-cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94(12), 4195-4201 (1999).
90. Nicolaou F, Teodoridis JM, Park H et al. CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. Blood 101(10), 4033-4041 (2003).